Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: Performance of HPV and pap cotesting in posttreatment management

Journal of Lower Genital Tract Disease

Volumn 17, Issue 5 SUPPL.1, 2013, Pages

  Katki, Hormuzd A ^a   Schiffman, Mark ^a   Castle, Philip E ^b   Fetterman, Barbara ^c   Poitras, Nancy E ^c   Lorey, Thomas ^c   Cheung, Li C ^d   Raine Bennett, Tina ^e   Gage, Julia C ^a   Kinney, Walter K ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c Regional Laboratory   (United States)

^d INFORMATION MANAGEMENT SERVICES INC   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Cancer prevention; Cervical intraepithelial neoplasia (CIN); Human papillomavirus (HPV); Pap; Posttreatment; Test of cure

Indexed keywords

ADENOCARCINOMA; ADENOCARCINOMA IN SITU; ADULT; ARTICLE; ATYPICAL GLANDULAR CELL; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTEGRATED HEALTH CARE SYSTEM; KAISER PERMANENTE NORTHERN CALIFORNIA SYSTEM; LOW GRADE SQUAMOUS INTRAEPITHELIAL LESION; PAPANICOLAOU TEST; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; RECURRENCE; RISK ASSESSMENT; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; VIROLOGY;

EID: 84876118890     PISSN: 10892591     EISSN: 15260976     Source Type: Journal    
DOI: 10.1097/LGT.0b013e31828543c5     Document Type: Article

References (26)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370: 890-907.
2. Kocken M, Helmerhorst TJM, Berkhof J, Louwers JA, Nobbenhuis MAE, Bais AG, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12: 441-50.
3. Soutter WP, de Barros Lopes A, Fletcher A, Monaghan JM, Duncan ID, Paraskevaidis E, et al. Invasive cervical cancer after conservative therapy for cervical intraepithelial neoplasia. Lancet 1997;349: 978-80.
4. Paraskevaidis E, Arbyn M, Sotiriadis A, Diakomanolis E, Martin-Hirsch P, Koliopoulos G, et al. The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004; 30: 205-11.
5. Nobbenhuis MAE, Meijer C, van den Brule AJC, Rozendaal L, Voorhorst FJ, Risse EKJ, et al. Addition of highrisk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001;84: 796-801.
6. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for highgrade CIN: an update of pooled evidence. Gynecol Oncol 2005;99:S7-11.
7. Strander B, Ryd W, Wallin KL, Warleby B, Zheng BY, Milsom I, et al. Does HPV-status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence? Eur J Cancer 2007;43: 1849-55.
8. Leguevaque P, Motton S, Decharme A, Soule-Tholy M, Escourrou G, Hoff J. Predictors of recurrence in high-grade cervical lesions and a plan of management. Eur J Surg Oncol 2010;36: 1073-9.
9. Kitchener HC, Walker PG, Nelson L, Hadwin R, Patnick J, Anthony GB, et al. HPV testing as an adjunct to cytology in the follow up of women treated for cervical intraepithelial neoplasia. BJOG 2008;115: 1001-7.
10. Jones J, Saleem A, Rai N, Shylasree TS, Ashman S, Gregory K, et al. Human Papillomavirus genotype testing combined with cytology as a 'test of cure' post treatment: the importance of a persistent viral infection. J Clin Virol 2011; 52: 88-92.
11. Gok M, Coupe VMH, Berkhof J, Verheijen RHM, Helmerhorst TJM, Hogewoning CJA, et al. HPV16 and increased risk of recurrence after treatment for CIN. Gynecol Oncol 2007;104: 273-5.
12. Dogan NU, Salman MC, Yuce K. The role ofHPVDNA testing in the follow-up of cervical intraepithelial neoplasia after loop electrosurgical excision procedure. Arch Gynecol Obstet 2011;283: 871-7.
13. Coupe VMH, Berkhof J, Verheijen RHM, Meijer C. Cost-effectiveness of human papillomavirus testing after treatment for cervical intraepithelial neoplasia. BJOG 2007;114: 416-24.
14. Brismar S, Johansson B, Borjesson M, Arbyn M, Andersson S. Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 2009;201.
15. Valasoulis G, Koliopoulos G, Founta C, Kyrgiou M, Tsoumpou I, Valari O, et al. Alterations in human papillomavirus- related biomarkers after treatment of cervical intraepithelial neoplasia. Gynecol Oncol 2011;121: 43-8.
16. Ryu A, Nam K, Kwak J, Kim J, Jeon S. Early human papillomavirus testing predicts residual/recurrent disease after LEEP. J Gynecol Oncol 2012;23: 217-25.
17. Moore EE, Danielewski JA, Garland SM, Tan J, Quinn MA, Stevens MP, et al. Clearance of human papillomavirus in women treated for cervical dysplasia. Obstet Gynecol 2011; 117: 101-8.
18. Kreimer AR, Schiffman M, Herrero R, Hildesheim A, Gonzalez P, Burk RD, et al. Long-term risk of recurrent cervical human papillomavirus infection and precancer and cancer following excisional treatment. Int J Cancer 2012;131: 211-8.
19. Kocken M, Uijterwaal MH, de Vries ALM, Berkhof J, Ket JCF, Helmerhorst TJM, et al. High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: a systematic review and meta-analysis. Gynecol Oncol 2012; 125: 500-7.
20. Chan BKS, Melnikow J, Slee CA, Arellanes R, Sawaya GF. Posttreatment human papillomavirus testing for recurrent cervical intraepithelial neoplasia: a systematic review. Am J Obstet Gynecol 2009;200: 422.e1-9.
21. Bais AG, Eijkemans MJC, Rebolj M, Snijders PJF, Verheijen RHM, van BallegooijenM, et al. Post-treatment CIN: randomised clinical trial using hrHPV testing for prediction of residual/recurrent disease. Int J Cancer 2009;124: 889-95.
22. Kreimer AR, Guido RS, Solomon D, Schiffman M, Wacholder S, Jeronimo J, et al. Human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease. Cancer Epidemiol Biomarkers Prev 2006;15: 908-14.
23. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines J Low Genit Tract Dis 2013;17:S28YS35.
24. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002;287: 2114-9.
25. Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, et al. Five-year risks of CIN3+ and cervical cancer among women with HPV testing of ASC-US Pap Results. J Low Genit Tract Dis 2013;17:S36YS42.
26. Darragh TM, Colgan TJ, Cox JT, Heller DS, Henry MR, Luff RD, et al. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. J Low Genit Tract Dis 2012;16: 205-42.